[31-411-pm] Pharmacotherapies (Personalized therapies) 1

[31-411-pm10] Measurement of serum Infliximab and Interleukin-6 concentrations predicts continuation of Infliximab treatment in patients with Rheumatoid Arthritis

○Sho Masui^1,2,3, Miyuki Nakamura^2,3, Akira Onishi⁴, Motomu Hashimoto^4,5, Hideo Onizawa⁴, Takayuki Fujii^4,6, Kosaku Murakami⁷, Koichi Murata^4,6, Masao Tanaka⁴, Kotoko Yokoyama⁸, Noriko Iwamoto⁸, Takashi Shimada⁸, Kotaro Itohara², Daiki Hira², Shunsaku Nakagawa², Satoshi Imai², Takayuki Nakagawa², Makoto Hayakari², Shuichi Matsuda⁶, Akio Morinobu^4,9, Tomohiro Terada², Kazuo Matsubara², Atsushi Yonezawa^1,2,3 (1. Sch. Pharm. Sci., Keio Univ., 2. Dept. Pharm., Kyoto Univ. Hospital., 3. Grad. Sch. Pharm. Sci., Kyoto Univ., 4. Center for Rheumatic Diseases, Kyoto Univ. Hospital., 5. Dept. Clin. Immunol., Osaka Metro. Univ. Hospital., 6. Dept. Ortho. Surg., Kyoto Univ. Hospital., 7. Center for Cancer Immunotherapy and Immunobiology, Kyoto Univ. Hospital., 8. Shimadzu Corp., 9. Dept. Rheumatol. & Clin Immunol., Kyoto Univ. Hospital.)